entecavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals carbocyclic nucleosides 1019 142217-69-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • entecavir monohydrate
  • anhydrous entecavir
  • BMS-200475-01
  • entecavir
  • baraclude
  • entecavir hydrate
Entecavir, a guanosine nucleoside analogue with activity against HBV reverse transcriptase, is efficiently phosphorylated to the active triphosphate form, which has an intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine triphosphate, entecavir triphosphate functionally inhibits all three activities of the HBV reverse transcriptase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Entecavir triphosphate is a weak inhibitor of cellular DNA polymerases alpha, beta, and delta and mitochondrial DNA polymerase gamma with Ki values ranging from 18 to > 160 microM.
  • Molecular weight: 277.28
  • Formula: C12H15N5O3
  • CLOGP: -1.78
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 125.76
  • ALOGS: -1.63
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.05 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class EIF2AK3,GRK2,PDK1,PDK2 4
kinase-selectivity-class AXL,CDK16,CDK2,CDK3,CDK9,GRK2,MAP3K21,PDK1 8
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
March 29, 2005 FDA BRISTOL MYERS SQUIBB
June 26, 2006 EMA BRISTOL-MYERS SQUIBB PHARMA EEIG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatitis B 161.00 19.83 42 6737 4477 90617191
Hepatitis B reactivation 137.07 19.83 36 6743 3938 90617730
Drug resistance 129.04 19.83 57 6722 30392 90591276
Hepatocellular carcinoma 103.29 19.83 26 6753 2402 90619266
Hepatitis B DNA increased 103.03 19.83 18 6761 272 90621396
Viral load increased 98.74 19.83 23 6756 1533 90620135
Platelet count decreased 90.92 19.83 78 6701 136891 90484777
Neutrophil count decreased 83.40 19.83 57 6722 71475 90550193
Hypophosphataemia 80.10 19.83 33 6746 14821 90606847
Exposure via body fluid 77.46 19.83 16 6763 608 90621060
Neutropenia 73.14 19.83 87 6692 224817 90396851
Viral mutation identified 63.42 19.83 17 6762 2008 90619660
White blood cell count decreased 63.34 19.83 70 6709 167039 90454629
Febrile neutropenia 61.17 19.83 67 6712 158282 90463386
Fanconi syndrome acquired 55.97 19.83 14 6765 1260 90620408
Hepatic failure 54.37 19.83 35 6744 39693 90581975
Abortion induced 52.74 19.83 23 6756 11865 90609803
Hepatic cancer 52.55 19.83 18 6761 4863 90616805
Hepatic function abnormal 47.20 19.83 34 6745 46254 90575414
Pathogen resistance 47.06 19.83 19 6760 8096 90613572
Lymphocyte count decreased 45.80 19.83 30 6749 35020 90586648
Liver transplant 43.31 19.83 13 6766 2304 90619364
Pulmonary microemboli 42.51 19.83 5 6774 0 90621668
Mixed liver injury 41.31 19.83 17 6762 7606 90614062
Osteomalacia 40.14 19.83 10 6769 885 90620783
Leukopenia 39.53 19.83 43 6736 100667 90521001
Thrombocytopenia 39.27 19.83 62 6717 208663 90413005
Anaemia 37.59 19.83 82 6697 352720 90268948
Blood creatinine increased 37.56 19.83 42 6737 101344 90520324
Hepatic encephalopathy 37.43 19.83 19 6760 13753 90607915
Alanine aminotransferase increased 37.12 19.83 45 6734 118293 90503375
Renal impairment 32.92 19.83 40 6739 105381 90516287
Agranulocytosis 31.83 19.83 24 6755 34978 90586690
Cardiac failure 31.70 19.83 40 6739 109456 90512212
Hypoproteinaemia 31.55 19.83 11 6768 3131 90618537
Abortion spontaneous 30.27 19.83 28 6751 54028 90567640
Hypokalaemia 27.53 19.83 41 6738 131075 90490593
Pregnancy on contraceptive 27.41 19.83 8 6771 1287 90620381
Excessive dynamic airway collapse 26.52 19.83 4 6775 22 90621646
Hepatitis C 25.26 19.83 11 6768 5649 90616019
Hypoalbuminaemia 24.23 19.83 15 6764 15882 90605786
Acute hepatic failure 23.97 19.83 17 6762 22544 90599124
Hepatitis D 23.83 19.83 4 6775 47 90621621
Systemic infection 23.69 19.83 10 6769 4765 90616903
Urinary tract stoma complication 23.38 19.83 4 6775 53 90621615
Blood bilirubin increased 23.34 19.83 22 6757 43448 90578220
Death 23.27 19.83 81 6698 456470 90165198
Cytokine release syndrome 22.85 19.83 18 6761 27955 90593713
Gastroenteritis staphylococcal 21.74 19.83 4 6775 82 90621586
Cryoglobulinaemia 21.64 19.83 6 6773 804 90620864
Septic shock 21.63 19.83 29 6750 84131 90537537
Swelling 21.37 19.83 3 6776 419055 90202613
Maternal exposure during pregnancy 21.11 19.83 67 6712 359996 90261672
Immune-mediated lung disease 20.50 19.83 7 6772 1873 90619795
Hyperuricaemia 20.42 19.83 10 6769 6709 90614959
Fanconi syndrome 20.27 19.83 7 6772 1936 90619732
Electrocardiogram P pulmonale 20.13 19.83 3 6776 15 90621653
Genotype drug resistance test positive 20.05 19.83 5 6774 444 90621224

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 334.70 16.60 117 13032 8077 42600109
Drug resistance 333.50 16.60 177 12972 34071 42574115
Viral mutation identified 269.65 16.60 80 13069 3251 42604935
Hepatic cancer 242.02 16.60 93 13056 8387 42599799
Hepatic failure 206.88 16.60 135 13014 37965 42570221
Hepatitis B DNA increased 203.30 16.60 45 13104 544 42607642
Genotype drug resistance test 178.32 16.60 29 13120 45 42608141
Hepatitis B reactivation 170.25 16.60 61 13088 4517 42603669
Hepatitis B 157.81 16.60 64 13085 6647 42601539
Pathogen resistance 148.77 16.60 72 13077 11378 42596808
Hepatic encephalopathy 116.34 16.60 69 13080 16373 42591813
Viral load increased 115.46 16.60 41 13108 2956 42605230
Osteomalacia 111.32 16.60 30 13119 854 42607332
Fanconi syndrome acquired 109.84 16.60 36 13113 2034 42606152
Ascites 104.62 16.60 107 13042 56571 42551615
Hepatic cirrhosis 95.24 16.60 65 13084 19637 42588549
Hepatic function abnormal 85.58 16.60 92 13057 51475 42556711
Blood HIV RNA decreased 85.01 16.60 12 13137 0 42608186
Multiple-drug resistance 83.08 16.60 42 13107 7280 42600906
Genotype drug resistance test positive 80.63 16.60 25 13124 1179 42607007
Hypophosphataemia 71.49 16.60 56 13093 20889 42587297
Hepatitis B surface antigen positive 61.15 16.60 13 13136 128 42608058
Blood phosphorus decreased 54.03 16.60 25 13124 3568 42604618
Alanine aminotransferase increased 49.76 16.60 94 13055 88312 42519874
Blood bilirubin increased 49.39 16.60 63 13086 42189 42565997
Portal vein thrombosis 48.42 16.60 25 13124 4524 42603662
Oesophageal varices haemorrhage 44.78 16.60 22 13127 3585 42604601
Platelet count decreased 42.74 16.60 116 13033 138465 42469721
Fanconi syndrome 41.79 16.60 17 13132 1777 42606409
Osteoporosis 40.67 16.60 35 13114 14871 42593315
Autoimmune haemolytic anaemia 40.62 16.60 24 13125 5647 42602539
Palmar-plantar erythrodysaesthesia syndrome 38.18 16.60 39 13110 20543 42587643
Viral infection 37.06 16.60 40 13109 22443 42585743
Renal impairment 35.72 16.60 94 13055 110134 42498052
Hypoalbuminaemia 35.36 16.60 33 13116 15577 42592609
White blood cell count decreased 34.61 16.60 93 13056 110303 42497883
Proteinuria 32.92 16.60 38 13111 22945 42585241
Aspartate aminotransferase increased 30.48 16.60 71 13078 77092 42531094
Lymphocyte count decreased 30.20 16.60 40 13109 27769 42580417
Mycoplasma infection 29.37 16.60 10 13139 635 42607551
Hypokalaemia 28.33 16.60 66 13083 71655 42536531
Portal vein occlusion 27.29 16.60 6 13143 70 42608116
Meningitis cryptococcal 26.45 16.60 15 13134 3268 42604918
Asymptomatic viral hepatitis 26.00 16.60 5 13144 28 42608158
Neutrophil count decreased 25.75 16.60 59 13090 63356 42544830
Parotid gland haemorrhage 25.70 16.60 5 13144 30 42608156
Hepatorenal syndrome 25.62 16.60 14 13135 2840 42605346
Optic disc hyperaemia 24.67 16.60 4 13145 6 42608180
Malignant anorectal neoplasm 24.34 16.60 5 13144 41 42608145
Hypocalciuria 23.63 16.60 4 13145 9 42608177
Liver transplant 23.60 16.60 13 13136 2678 42605508
Hepatitis B e antigen positive 23.54 16.60 5 13144 49 42608137
Retinal toxicity 23.33 16.60 8 13141 519 42607667
Retinopathy hypertensive 22.93 16.60 7 13142 313 42607873
Renal tubular injury 22.53 16.60 11 13138 1768 42606418
Hepatitis B virus test positive 22.31 16.60 7 13142 343 42607843
Jaundice 22.25 16.60 39 13110 34550 42573636
Drug abuse 22.22 16.60 3 13146 104768 42503418
Renal glycosuria 22.11 16.60 4 13145 15 42608171
Retinal depigmentation 21.77 16.60 5 13144 72 42608114
Liver transplant rejection 21.65 16.60 12 13137 2501 42605685
Foetal hypokinesia 21.57 16.60 7 13142 383 42607803
Mitochondrial myopathy 21.38 16.60 6 13143 199 42607987
Foetal heart rate abnormal 21.27 16.60 6 13143 203 42607983
Monkeypox 21.16 16.60 7 13142 407 42607779
Renal tubular acidosis 20.65 16.60 12 13137 2738 42605448
Blood alkaline phosphatase increased 20.47 16.60 37 13112 33560 42574626
Varices oesophageal 20.13 16.60 14 13135 4351 42603835
Venoocclusive liver disease 19.98 16.60 20 13129 10282 42597904
Completed suicide 19.90 16.60 3 13146 96462 42511724
Nephropathy toxic 19.49 16.60 25 13124 16813 42591373
Starvation 19.39 16.60 7 13142 529 42607657
Antiviral drug level below therapeutic 19.17 16.60 3 13146 3 42608183
Blood uric acid 19.17 16.60 3 13146 3 42608183
Cancer surgery 19.17 16.60 7 13142 546 42607640
Chronic hepatitis B 19.02 16.60 5 13144 129 42608057
Immunosuppressant drug level increased 18.78 16.60 17 13132 7714 42600472
Dyspnoea 18.63 16.60 72 13077 442549 42165637
Schistosomiasis 18.41 16.60 4 13145 44 42608142
HIV associated nephropathy 18.15 16.60 6 13143 348 42607838
Alkalosis hypokalaemic 17.96 16.60 3 13146 6 42608180
Laryngeal erythema 17.96 16.60 3 13146 6 42608180
Hypoproteinaemia 17.81 16.60 11 13138 2801 42605385
COVID-19 pneumonia 17.44 16.60 27 13122 21586 42586600
Febrile neutropenia 17.23 16.60 107 13042 185596 42422590
Toxicity to various agents 16.83 16.60 28 13121 229108 42379078
Amylase increased 16.75 16.60 15 13134 6714 42601472
Malaria 16.61 16.60 5 13144 213 42607973

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 428.39 15.25 127 18094 9753 110561325
Viral mutation identified 354.16 15.25 92 18129 4327 110566751
Hepatic cancer 317.83 15.25 104 18117 11052 110560026
Hepatitis B reactivation 310.51 15.25 93 18128 7391 110563687
Drug resistance 288.33 15.25 154 18067 56220 110514858
Hepatic failure 278.29 15.25 161 18060 68578 110502500
Hepatitis B DNA increased 249.69 15.25 51 18170 804 110570274
Pathogen resistance 194.80 15.25 82 18139 17590 110553488
Hepatitis B 174.43 15.25 64 18157 9548 110561530
Hepatic encephalopathy 158.05 15.25 82 18139 28174 110542904
Viral load increased 157.52 15.25 46 18175 3344 110567734
Fanconi syndrome acquired 153.56 15.25 44 18177 2990 110568088
Platelet count decreased 149.73 15.25 187 18034 230256 110340822
Hypophosphataemia 148.40 15.25 83 18138 33099 110537979
Hepatic function abnormal 140.60 15.25 117 18104 89178 110481900
Osteomalacia 131.80 15.25 34 18187 1553 110569525
Ascites 124.57 15.25 111 18110 92697 110478381
Genotype drug resistance test positive 101.73 15.25 27 18194 1379 110569699
White blood cell count decreased 96.30 15.25 151 18070 229239 110341839
Neutrophil count decreased 94.67 15.25 108 18113 120833 110450245
Renal impairment 90.37 15.25 132 18089 188313 110382765
Alanine aminotransferase increased 88.52 15.25 129 18092 183644 110387434
Multiple-drug resistance 87.44 15.25 43 18178 13192 110557886
Blood bilirubin increased 84.78 15.25 82 18139 75890 110495188
Lymphocyte count decreased 81.86 15.25 71 18150 57172 110513906
Blood HIV RNA decreased 77.11 15.25 10 18211 0 110571078
Febrile neutropenia 75.16 15.25 163 18058 316604 110254474
Hepatic cirrhosis 68.05 15.25 69 18152 67557 110503521
Hypoalbuminaemia 67.61 15.25 48 18173 28926 110542152
Portal vein thrombosis 65.46 15.25 29 18192 7029 110564049
Oesophageal varices haemorrhage 64.87 15.25 26 18195 4919 110566159
Hypokalaemia 64.24 15.25 111 18110 182337 110388741
Neutropenia 62.25 15.25 168 18053 374452 110196626
Hepatitis B surface antigen positive 59.36 15.25 12 18209 179 110570899
Liver transplant 56.32 15.25 23 18198 4566 110566512
Hypoproteinaemia 53.76 15.25 24 18197 5921 110565157
Blood creatinine increased 51.43 15.25 101 18120 182788 110388290
Thrombocytopenia 50.63 15.25 149 18072 348736 110222342
Proteinuria 49.99 15.25 46 18175 39972 110531106
Jaundice 48.19 15.25 54 18167 59182 110511896
Fanconi syndrome 47.89 15.25 19 18202 3500 110567578
Palmar-plantar erythrodysaesthesia syndrome 47.11 15.25 45 18176 40980 110530098
Aspartate aminotransferase increased 47.01 15.25 90 18131 159846 110411232
Joint swelling 45.24 15.25 9 18212 442836 110128242
Septic shock 44.29 15.25 87 18134 157441 110413637
Blood phosphorus decreased 42.14 15.25 22 18199 7643 110563435
Autoimmune haemolytic anaemia 40.72 15.25 24 18197 10543 110560535
Blood alkaline phosphatase increased 38.86 15.25 53 18168 70882 110500196
Death 38.54 15.25 221 18000 698648 109872430
Rheumatoid arthritis 38.02 15.25 3 18218 299610 110271468
Nasopharyngitis 36.35 15.25 10 18211 394351 110176727
Drug intolerance 36.19 15.25 11 18210 406501 110164577
Drug hypersensitivity 35.81 15.25 15 18206 454075 110117003
Leukopenia 35.72 15.25 77 18144 148714 110422364
Anaemia 35.55 15.25 181 18040 546905 110024173
Portal vein occlusion 35.38 15.25 7 18214 93 110570985
Pyrexia 34.85 15.25 260 17961 898005 109673073
Hypocalcaemia 34.54 15.25 48 18173 65318 110505760
Pain 34.23 15.25 66 18155 954889 109616189
Liver transplant rejection 32.84 15.25 15 18206 3903 110567175
Acute hepatic failure 32.71 15.25 35 18186 36433 110534645
Swelling 32.16 15.25 9 18212 351032 110220046
Cytokine release syndrome 31.86 15.25 48 18173 70258 110500820
Anxiety 31.33 15.25 9 18212 345069 110226009
Transaminases increased 31.20 15.25 45 18176 63345 110507733
Systemic lupus erythematosus 31.04 15.25 3 18218 254335 110316743
Hepatorenal syndrome 30.55 15.25 15 18206 4582 110566496
Blood creatine phosphokinase increased 30.46 15.25 48 18173 73029 110498049
Meningitis cryptococcal 30.05 15.25 15 18206 4747 110566331
Arthralgia 29.59 15.25 52 18169 779580 109791498
Therapeutic product effect decreased 29.50 15.25 3 18218 244313 110326765
Arthropathy 29.02 15.25 6 18215 287516 110283562
Pulmonary microemboli 28.98 15.25 5 18216 29 110571049
Parotid gland haemorrhage 28.69 15.25 5 18216 31 110571047
Plasma cell myeloma 28.56 15.25 43 18178 62893 110508185
Sinusitis 28.33 15.25 7 18214 296681 110274397
Musculoskeletal stiffness 27.91 15.25 6 18215 279816 110291262
Abortion induced 27.76 15.25 17 18204 8002 110563076
Hyperuricaemia 27.01 15.25 21 18200 14510 110556568
Varices oesophageal 26.79 15.25 16 18205 7199 110563879
Wheezing 26.44 15.25 5 18216 255225 110315853
Monkeypox 26.21 15.25 7 18214 366 110570712
Antiviral drug level below therapeutic 26.06 15.25 5 18216 56 110571022
Mixed liver injury 25.87 15.25 19 18202 12060 110559018
Liver abscess 25.75 15.25 16 18205 7723 110563355
Interstitial lung disease 25.66 15.25 65 18156 139269 110431809
COVID-19 pneumonia 25.43 15.25 31 18190 37112 110533966
Confusional state 25.25 15.25 24 18197 468656 110102422
Malignant anorectal neoplasm 24.64 15.25 5 18216 76 110571002
Renal tubular acidosis 24.41 15.25 13 18208 4702 110566376
Immunosuppressant drug level increased 24.11 15.25 18 18203 11706 110559372
Product substitution issue 24.05 15.25 24 18197 23037 110548041
Optic disc hyperaemia 24.03 15.25 4 18217 18 110571060
Nephropathy toxic 23.99 15.25 26 18195 27452 110543626
Infusion related reaction 23.64 15.25 17 18204 381145 110189933
Pregnancy on contraceptive 23.17 15.25 8 18213 1000 110570078
Hepatitis B e antibody positive 23.13 15.25 3 18218 0 110571078
Retinopathy hypertensive 23.06 15.25 7 18214 581 110570497
Cytomegalovirus infection reactivation 22.75 15.25 21 18200 18312 110552766
Lower respiratory tract infection 22.70 15.25 6 18215 243100 110327978
Renal glycosuria 22.53 15.25 4 18217 28 110571050
Gamma-glutamyltransferase increased 22.47 15.25 38 18183 61271 110509807
Agranulocytosis 22.27 15.25 38 18183 61722 110509356
Venoocclusive liver disease 22.01 15.25 19 18202 15188 110555890
Excessive dynamic airway collapse 21.85 15.25 4 18217 34 110571044
Cryptococcosis 21.83 15.25 12 18209 4619 110566459
HIV associated nephropathy 21.73 15.25 6 18215 356 110570722
Hypocalciuria 21.64 15.25 4 18217 36 110571042
Blood uric acid 21.06 15.25 3 18218 3 110571075
Amylase increased 20.93 15.25 17 18204 12502 110558576
Renal failure 20.71 15.25 83 18138 226491 110344587
Mycoplasma infection 20.61 15.25 8 18213 1390 110569688
Myelosuppression 20.58 15.25 47 18174 94293 110476785
Blood cholesterol increased 20.51 15.25 3 18218 184782 110386296
Acute kidney injury 20.26 15.25 176 18045 635254 109935824
Abdominal discomfort 20.25 15.25 21 18200 393837 110177241
Renal tubular injury 20.23 15.25 10 18211 3098 110567980
Schistosomiasis 20.16 15.25 4 18217 54 110571024
Asthma 20.15 15.25 8 18213 250283 110320795
Immune-mediated hepatitis 20.15 15.25 13 18208 6698 110564380
Cancer surgery 19.50 15.25 7 18214 980 110570098
Hepatitis B virus test positive 19.42 15.25 6 18215 528 110570550
Retinal toxicity 19.29 15.25 8 18213 1651 110569427
Starvation 19.26 15.25 7 18214 1016 110570062
Peripheral swelling 19.18 15.25 23 18198 404011 110167067
Therapeutic embolisation 18.83 15.25 6 18215 584 110570494
Metastases to lung 18.71 15.25 21 18200 23042 110548036
Vomiting 18.63 15.25 82 18139 910593 109660485
Depression 18.59 15.25 15 18206 317320 110253758
Multiple organ dysfunction syndrome 18.45 15.25 61 18160 151649 110419429
Hypersensitivity 18.13 15.25 24 18197 403974 110167104
Pneumonia bacterial 18.11 15.25 22 18199 26239 110544839
Cytomegalovirus infection 17.68 15.25 32 18189 54412 110516666
Hepatectomy 17.54 15.25 5 18216 333 110570745
Urinary tract stoma complication 17.46 15.25 4 18217 110 110570968
Cardiac failure 17.35 15.25 69 18152 187557 110383521
Retinal depigmentation 17.15 15.25 5 18216 361 110570717
Bone pain 17.12 15.25 35 18186 65098 110505980
Hyperbilirubinaemia 16.92 15.25 23 18198 30648 110540430
Haemolytic anaemia 16.89 15.25 19 18202 20901 110550177
Weight increased 16.80 15.25 27 18194 419617 110151461
Lactic acidosis 16.77 15.25 43 18178 92768 110478310
Renal tubular disorder 16.62 15.25 12 18209 7417 110563661
Hyperphosphaturia 16.62 15.25 4 18217 137 110570941
Sleep disorder 16.57 15.25 6 18215 198638 110372440
Toxicity to various agents 16.49 15.25 34 18187 480521 110090557
Dyspnoea 16.40 15.25 111 18110 1106761 109464317
Malaria 16.39 15.25 5 18216 422 110570656
Urine protein/creatinine ratio increased 16.33 15.25 7 18214 1566 110569512
Pneumonia 16.32 15.25 218 18003 876496 109694582
Hypophosphataemic osteomalacia 16.28 15.25 5 18216 432 110570646
Alkalosis hypokalaemic 16.23 15.25 3 18218 27 110571051
Mitochondrial myopathy 16.09 15.25 5 18216 449 110570629
Haemorrhagic cholecystitis 15.90 15.25 4 18217 165 110570913
Blister 15.65 15.25 9 18212 227367 110343711
Injection site pain 15.49 15.25 5 18216 177917 110393161
Contraindicated product administered 15.48 15.25 11 18210 248256 110322822
Drug abuse 15.42 15.25 5 18216 177406 110393672
Loss of personal independence in daily activities 15.40 15.25 3 18218 150017 110421061
Ileal ulcer 15.36 15.25 7 18214 1810 110569268
Immune-mediated lung disease 15.25 15.25 10 18211 5293 110565785

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AF10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:59897 EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
CHEBI has role CHEBI:64951 anti-HBV agent

Related Drugs by ATC class:

J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 12 drugs
abacaviradefovir dipivoxilclevudinedidanosineemtricitabinelamivudinestavudinetelbivudinetenofovir alafenamidetenofovir disoproxilzalcitabinezidovudine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Lamivudine-Refractory Chronic Hepatitis B indication
Lactic acidosis contraindication 91273001 DOID:3650
Liver function tests abnormal contraindication 166603001
Steatosis of liver contraindication 197321007
Impaired renal function disorder contraindication 197663003
Drug Resistance to Anti-retroviral Therapy contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.56 acidic
pKa2 12.33 acidic
pKa3 13.37 acidic
pKa4 4.58 Basic
pKa5 3.37 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein P Polyprotein INHIBITOR CHEMBL CHEMBL
Protein P Polyprotein WOMBAT-PK
Capsid protein Structural EC50 9.62 CHEMBL

External reference:

IDSource
4024911 VUID
N0000171606 NUI
D04008 KEGG_DRUG
4024911 VANDF
C0971023 UMLSCUI
CHEBI:59902 CHEBI
CHEMBL5314362 ChEMBL_ID
CHEMBL713 ChEMBL_ID
DB00442 DRUGBANK_ID
C413685 MESH_SUPPLEMENTAL_RECORD_UI
135398508 PUBCHEM_CID
5968Y6H45M UNII
1546027 RXNORM
19722 MMSL
228280 MMSL
67562 MMSL
d05525 MMSL
010730 NDDF
1269008001 SNOMEDCT_US
416248007 SNOMEDCT_US
416644000 SNOMEDCT_US
725853008 SNOMEDCT_US
209216-23-9 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
BARACLUDE HUMAN PRESCRIPTION DRUG LABEL 1 0003-1611 TABLET, FILM COATED 0.50 mg ORAL NDA 27 sections
BARACLUDE HUMAN PRESCRIPTION DRUG LABEL 1 0003-1612 TABLET, FILM COATED 1 mg ORAL NDA 27 sections
BARACLUDE HUMAN PRESCRIPTION DRUG LABEL 1 0003-1614 SOLUTION 0.05 mg ORAL NDA 27 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 10135-615 TABLET, FILM COATED 0.50 mg ORAL ANDA 29 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 10135-616 TABLET, FILM COATED 1 mg ORAL ANDA 29 sections
ENTECAVIR HUMAN PRESCRIPTION DRUG LABEL 1 16714-717 TABLET, FILM COATED 0.50 mg ORAL ANDA 26 sections
ENTECAVIR HUMAN PRESCRIPTION DRUG LABEL 1 16714-718 TABLET, FILM COATED 1 mg ORAL ANDA 26 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 42291-261 TABLET, FILM COATED 0.50 mg ORAL ANDA 28 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 42291-262 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 42806-658 TABLET 0.50 mg ORAL ANDA 28 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 42806-659 TABLET 1 mg ORAL ANDA 28 sections
ENTECAVIR HUMAN PRESCRIPTION DRUG LABEL 1 50771-013 TABLET, FILM COATED 0.50 mg ORAL ANDA 28 sections
ENTECAVIR HUMAN PRESCRIPTION DRUG LABEL 1 50771-014 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 51407-589 TABLET 0.50 mg ORAL ANDA 19 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 60687-216 TABLET 0.50 mg ORAL ANDA 26 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 61442-311 TABLET 0.50 mg ORAL ANDA 19 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 65162-446 TABLET, FILM COATED 0.50 mg ORAL ANDA 26 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 65162-449 TABLET, FILM COATED 1 mg ORAL ANDA 26 sections
Entecavir Human Prescription Drug Label 1 65862-841 TABLET 0.50 mg ORAL ANDA 26 sections
Entecavir Human Prescription Drug Label 1 65862-842 TABLET 1 mg ORAL ANDA 26 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 68382-920 TABLET, FILM COATED 0.50 mg ORAL ANDA 24 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 68382-921 TABLET, FILM COATED 1 mg ORAL ANDA 24 sections
ENTECAVIR HUMAN PRESCRIPTION DRUG LABEL 1 69097-425 TABLET, FILM COATED 1 mg ORAL ANDA 25 sections
ENTECAVIR HUMAN PRESCRIPTION DRUG LABEL 1 69097-426 TABLET, FILM COATED 0.50 mg ORAL ANDA 25 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 70771-1019 TABLET, FILM COATED 0.50 mg ORAL ANDA 1 sections
Entecavir HUMAN PRESCRIPTION DRUG LABEL 1 70771-1020 TABLET, FILM COATED 1 mg ORAL ANDA 1 sections